| Theme | Selection of New Drug for Calcium and Phosphate Disorder | |
|---|---|---|
| Title | Development and indications for new vitamin D analogues | |
| Publish Date | 2003/01 | |
| Author | Naohiko Kato | Division of Nephrology and Hypertension, The Jikei University School of Medicine |
| Author | Takashi Shigematsu | Division of Nephrology and Hypertension, The Jikei University School of Medicine |
| [ Summary ] | Several vitamin D analogues have been developed that maintain the direct suppressive effects of 1,25 dihydroxy-vitamin D3 on the parathyroid glands, but have less calcemic activity. Maxacalcitol (OCT) has the attribute of rapid clearance, which prevents sustained effects on intestinal Ca absorption and bone resorption, but still allows a prolonged supprresion of PTH gene expression and parathyroid cell growth. The calcemic activity of paricalcitol diminishes with the duration of treatment. The low toxicity of doxercalciferoi has been noted with chronic administration. Understanding how analogues exert their selective actions may allow for the design of more effective compounds for the treatment of secondary hyperparathyroidism. |
|